Amneal Pharmaceuticals (AMRX) and mAbxience announced that the FDA has approved its biologics licensing applications, or BLAs, for Boncresa and Oziltus. Under Amneal’s partnership with mAbxience, mAbxience is responsible for development and manufacturing, while Amneal holds exclusive U.S. commercialization rights.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces FDA approval for epinephrine injection vials
- Amneal Pharmaceuticals initiated with an Overweight at Barclays
- Amneal Pharmaceuticals announces results from Phase 4 ELEVATE-PD
- Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol
- Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise